WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck & Co., Inc. issued the following statement today on the Government of Brazil’s decision to issue a compulsory license for STOCRIN™ (efavirenz): “Merck is profoundly disappointed by the decision of the Government of Brazil (GOB) to issue a compulsory license for STOCRIN™ (efavirenz), which would break Merck & Co., Inc.’s patent and make it possible for efavirenz to be produced by a generic manufacturer.
